BioWorld

Nov. 10, 2008

Onyx Will Develop Cancer Drug in $320M BTG Deal

Onyx Pharmaceuticals Inc. took another step toward building its pipeline by licensing an anticancer compound from London-based BTG plc, in a deal that could bring in as much as $320 million for the UK company. (BioWorld Today) Read More

Tarceva Hits Endpoint in Phase III Maintenance Therapy NSCLC Trial

NewCo News: Stealth Blockmir Blocks miRNA One Target mRNA at a Time

Dingell, Waxman Fight for House Energy and Commerce Panel

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 12, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...

DEE-lightful: Praxis’ phase II results allow stock to flex its muscle

BioWorld

Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...